191 related articles for article (PubMed ID: 37563994)
1. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
Zhdanava M; Ding Z; Manceur AM; Zhao R; Holiday C; Kachroo S; Izanec J; Pilon D
Curr Med Res Opin; 2023 Sep; 39(9):1215-1225. PubMed ID: 37563994
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava M; Ding Z; Manceur AM; Muser E; Lefebvre P; Holiday C; Lafeuille MH; Pilon D
Curr Med Res Opin; 2023 Apr; 39(4):533-543. PubMed ID: 36752586
[TBL] [Abstract][Full Text] [Related]
3. Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava M; Zhao R; Manceur AM; Ding Z; Kachroo S; Holiday C; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Aug; 29(8):907-916. PubMed ID: 37523319
[No Abstract] [Full Text] [Related]
4. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.
Zhdanava M; Kachroo S; Manceur AM; Ding Z; Holiday C; Zhao R; Godwin B; Pilon D
Clin Ther; 2023 Aug; 45(8):770-777. PubMed ID: 37442653
[TBL] [Abstract][Full Text] [Related]
5. Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis.
Zhdanava M; Kachroo S; Shah A; Ding Z; Lefebvre P; Zhao R; Kerner C; Pilon D
Patient Prefer Adherence; 2024; 18():809-820. PubMed ID: 38617809
[TBL] [Abstract][Full Text] [Related]
6. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics.
Degli Esposti L; Daperno M; Dovizio M; Franchi A; Sangiorgi D; Savarino EV; Scaldaferri F; Secchi O; Serra A; Perrone V; Armuzzi A
Dig Liver Dis; 2023 Sep; 55(9):1214-1220. PubMed ID: 37100708
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
9. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.
Monin L; Dubois S; Reenaers C; Van Kemseke C; Latour P; Van Daele D; Vieujean S; Seidel L; Louis E
Dig Liver Dis; 2021 Jan; 53(1):72-78. PubMed ID: 33221330
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
13. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
[TBL] [Abstract][Full Text] [Related]
15. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia.
Sullivan J; Hannam S; Puig A; Maranta D; McGeachie AB; Baker C
Australas J Dermatol; 2023 Nov; 64(4):504-513. PubMed ID: 37705180
[TBL] [Abstract][Full Text] [Related]
19. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn's Disease: A Study Based on the Korean National Database.
Seo GH; Jung SH
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
